Nuclear heat shock protein 110 expression is associated with poor prognosis and hyperthermo-chemotherapy resistance in gastric cancer patients with peritoneal metastasis

Figure 3 Functional analysis of the MKN45 human gastric cancer cell line treated with KNK437 under hyperthermic conditions. A: Proliferation of MKN45 cells with and without KNK437-mediated HSP110 suppression. The results for normal (37 °C) (right panel) and hyperthermic (43 °C) (left panel) conditions are shown. Proliferation of MKN45 cells in the KNK437-mediated HSP110 suppression group (under hyperthermic condition) was significantly lower than that of the parental and control groups (^aP < 0.05); B: Cisplatin sensitivity in MKN45 cells in the presence or absence of KNK437-mediated HSP110 suppression. The results for normal (37 °C) (right panel) and hyperthermic (43 °C) (left panel) conditions are shown. Cisplatin sensitivity of MKN45 cells under the hyperthermic condition of 43 °C was significantly increased by KNK437-mediated HSP110 suppression (^aP < 0.05); C: Treatment of MKN45 cells with various therapeutic combinations. Therapeutic sensitivity of MKN45 cells treated with cisplatin and KNK437 under hyperthermic conditions was greater than that of cells with other therapeutic combinations (^aP < 0.05). HSP110: Heat shock protein 110; HT: Heat treatment.